Author/Authors :
Wang، نويسنده , , Yongming and Liang، نويسنده , , Wei-Ping and Lan، نويسنده , , Feng and Wu، نويسنده , , Haodi and Lisowski، نويسنده , , Leszek and Gu، نويسنده , , Mingxia and Hu، نويسنده , , Shijun and Kay، نويسنده , , Mark A. and Urnov، نويسنده , , Fyodor D. and Shinnawi، نويسنده , , Rami and Gold، نويسنده , , Joseph D. and Gepstein، نويسنده , , Lior and Wu، نويسنده , , Joseph C.، نويسنده ,
Abstract :
AbstractBackground
induced pluripotent stem cells (iPSCs) play an important role in disease modeling and drug testing. However, the current methods are time-consuming and lack an isogenic control.
ives
tudy sought to establish an efficient technology to generate human PSC-based disease models with isogenic control.
s
n channel genes KCNQ1 and KCNH2 with dominant negative mutations causing long QT syndrome types 1 and 2, respectively, were stably integrated into a safe harbor AAVS1 locus using zinc finger nuclease technology.
s
clamp recording revealed that the edited iPSC-derived cardiomyocytes (iPSC-CMs) displayed characteristic long QT syndrome phenotype and significant prolongation of the action potential duration compared with the unedited control cells. Finally, addition of nifedipine (L-type calcium channel blocker) or pinacidil (KATP-channel opener) shortened the action potential duration of iPSC-CMs, confirming the validity of isogenic iPSC lines for drug testing in the future.
sions
udy demonstrates that iPSC-CM-based disease models can be rapidly generated by overexpression of dominant negative gene mutants.
Keywords :
disease models , Drug testing , Genome editing , long QT syndrome , stem cells